WG
AMRX icon

Winton Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Winton Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Buy
144,816
+25,435
+21% +$349K 0.08% 259
2026
Q1 		$1.48M Buy
+119,381
New +$1.6M 0.05% 385
2025
Q4 		– Sell
-30,415
Closed -$304K – 921
2025
Q3 		$304K Buy
+30,415
New +$273K 0.01% 629
2023
Q4 		– Sell
-51,922
Closed -$219K – 738
2023
Q3 		$219K Buy
51,922
+32,854
+172% +$123K 0.02% 635
2023
Q2 		$59.1K Buy
+19,068
New +$40.6K ﹤0.01% 736
2021
Q3 		– Sell
-13,492
Closed -$69K – 1322
2021
Q2 		$69K Buy
13,492
+956
+8% +$5.43K ﹤0.01% 1396
2021
Q1 		$84K Buy
+12,536
New +$69.5K ﹤0.01% 1341
2020
Q4 		– Sell
-32,070
Closed -$124K – 1313
2020
Q3 		$124K Buy
+32,070
New +$137K ﹤0.01% 1385
2020
Q1 		– Sell
-22,729
Closed -$110K – 1391
2019
Q4 		$110K Buy
+22,729
New +$79K ﹤0.01% 1482

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Winton Group's AMRX Position: Q2 2026 in Review

Winton Group increased its Amneal Pharmaceuticals (AMRX) stake by 21% in Q2 2026, buying an estimated $349K and bringing the position to 144,816 shares worth $2.51M. The position accounts for 0.08% of the portfolio, ranked #259.

Winton Group first reported a position in AMRX in Q4 2019 and has held it in 9 quarters since. 219 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Winton Group held 144,816 shares of Amneal Pharmaceuticals worth $2.51M as of Q2 2026.
  • Winton Group bought 25,435 Amneal Pharmaceuticals shares in Q2 2026, an estimated $349K.
  • Amneal Pharmaceuticals made up 0.08% of Winton Group's portfolio in Q2 2026, its #259 holding.
  • Winton Group first reported a position in Amneal Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
  • 219 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.